首页> 外文期刊>Oncology letters >Role of serine/threonine kinase 33 methylation in colorectal cancer and its clinical significance
【24h】

Role of serine/threonine kinase 33 methylation in colorectal cancer and its clinical significance

机译:丝氨酸/苏氨酸激酶33在结直肠癌中甲基化的作用及其临床意义

获取原文
获取原文并翻译 | 示例
           

摘要

Serine/threonine kinase 33 (STK33) is a novel protein that has been the focus of an increasing number of studies in recent years; however, the role of STK33 in tumorigenesis remains controversial. Previous studies have demonstrated that STK33 is overexpressed in several human cancers and exerts a pro-tumorigenic effect through the promotion of cell proliferation. However, the role of STK33 in colorectal cancer (CRC), which is one of the most aggressive human malignancies, remains unclear. The aim of the current study was to investigate the methylation status of STK33 in CRC and to determine its clinical significance. The results demonstrated that STK33 was hypermethylated in CRC cell lines and promoted the proliferation of CRC cells. In addition, the methylation status and expression of STK33 in 94 pairs of cancer and noncancerous tissues obtained from patients with CRC was investigated. STK33 methylation was significantly increased in cancer tissues when compared with adjacent noncancerous tissues (P0.001). STK33 methylation was associated with lymph node metastasis (P0.05), tumor invasion (P0.05), distant metastases (P0.01) and tumor stage (P0.01). Reduced STK33 mRNA and protein expression in CRC was associated with STK33 hypermethylation (P0.001). In addition, patients with hypermethylated STK33 exhibited shorter overall survival rates when compared with those with unmethylated STK33 (P0.01). In conclusion, the results of the current study suggest that STK33 hypermethylation may be a promising novel biomarker for the diagnosis, prognosis and suitable treatment of CRC.
机译:丝氨酸/苏氨酸激酶33(STK33)是一种新的蛋白质,近年来一直是越来越多的研究的重点;然而,STK33在肿瘤发生中的作用仍然存在争议。以前的研究表明,STK33在几种人类癌症中过表达,并通过促进细胞增殖来施加促致瘤效果。然而,STK33在结肠直肠癌(CRC)中的作用,这是最具侵略性的人类恶性肿瘤之一仍然不清楚。目前研究的目的是研究CRC中STK33的甲基化状态,并确定其临床意义。结果证明,STK33在CRC细胞系中呈高甲基化,并促进了CRC细胞的增殖。此外,研究了94对癌症和从CRC患者获得的STK33中STK33的甲基化状态和表达。与相邻的非癌组织相比(P <0.001)相比,STK33甲基化在癌组织中显着增加。 STK33甲基化与淋巴结转移(P <0.05),肿瘤侵袭(P <0.05),远处转移(P <0.01)和肿瘤阶段(P <0.01)相关。 CRC中的STK33 mRNA和蛋白质表达减少与STK33高甲基化有关(P <0.001)。此外,与未甲基化的STK33(P <0.01)相比,患有高甲基化STK33的患者表现出较短的总存活率。总之,目前研究的结果表明,STK33高甲基化可能是一个有前途的新型生物标志物,用于诊断,预后和CRC的适当治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号